Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II

Japanese Journal of Cancer Research

Volumn 88, Issue 10, 1997, Pages 992-1002

  Utsugi, Teruhiro ^a   Aoyagi, Kumio ^a   Asao, Tetsuji ^a   Okazaki, Shinji ^a   Aoyagi, Yoshimi ^a   Sano, Masaki ^a   Wierzba, Konstanty ^a   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antitumor activity; Quinoline derivative; TAS 103; Topoisomerase I; Topoisomerase II

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; IRINOTECAN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CELL STRAIN KB; COLON TUMOR; CONTROLLED STUDY; DNA CLEAVAGE; DNA PROTEIN COMPLEX; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; LUNG METASTASIS; LUNG TUMOR; MALE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SOLID TUMOR; STOMACH TUMOR; TUMOR XENOGRAFT;

EID: 0030659850     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00320.x     Document Type: Article

References (42)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65, 635-692 (1996).
2. Osheroff, N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther., 41, 223-241 (1989).
3. Davies, S. M., Robson, C. N., Davies, S. L. and Hickson, I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem., 263, 17724-17729 (1988).
4. Deffie, A. M., Batra, J. K. and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49, 58-62 (1989).
5. Bjornsti, M.-A., Benedetti, P., Viglianti, G. A. and Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res., 49, 6318-6323 (1989).
6. Heck, M. M. S., Hittelman, W. N. and Earnshaw, W. C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA, 85, 1086-1090 (1988).
7. Chow, K.-C. and Ross, W. E. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol. Cell. Biol., 7, 3119-3123 (1987).
8. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048 (1989).
9. van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G. and de Vries, E. G. E. P-Glycoprotein expression and DNA topoisomerase I and II activity in benign tumor of the ovary and in malignant tumor of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920 (1991).
10. Potmesil, M., Hsiang, Y.-H., Liu, L. F., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenzar, T. J., Penziner, A., Kanganis, D., Knowles, D., Traganos, F. and Silber, R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res., 48, 3537-3543 (1988).
11. Holden, J. A., Rolfson, D. H. and Wittwer, C. T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry, 29, 2127-2134 (1990).
12. Husain, I., Mohler, J. L., Seigler, H. F. and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumor: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54, 539-546 (1994).
13. Beck, W. T., Cirtain, M. C., Danks, M. K., Felsted, R. L., Safa, A. R., Wolverton, J. S., Suttle, D. P. and Trent, J. M. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res., 47, 5455-5460 (1987).
14. Danks, M. K., Schmidt, C. A., Cirtain, M. C., Suttle, D. P. and Beck, W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemia cells selected for resistance to VM-26. Biochemistry, 27, 8861-8869 (1988).
15. Tan, K. B., Mattern, M. R., Eng, W.-K., McCabe, F. L. and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81, 1732-1735 (1989).
16. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F. and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50, 7962-7965 (1990).
17. Riou, J.-F., Helissey, P., Grondard, L. and GiorgiRenault, S. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol. Pharmacol., 40, 699-706 (1991).
18. Yamashita, Y., Kawada, S., Fujii, N. and Nakano, H. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry, 30, 5838-5845 (1991).
19. Larsen, A. K., Grondard, L., Couprie, J., Desoize, B., Comoe, L., Jardillier, J.-C. and Riou, J.-F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem. Pharmcol., 46, 1403-1412 (1993).
20. Poddevin, B., Riou, J.-F., Lavelle, F. and Pommier, Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol. Pharmacol., 44, 767-774 (1993).
21. Utsugi, T., Mattern, M. R., Mirabelli, C. K. and Hanna, N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res., 50, 2636-2640 (1990).
22. Utsugi, T., Shibata, J., Sugimoto, Y., Aoyagi, K., Wierzba, K., Kobunai, T., Terada, T., Oh-hara, T., Tsuruo, T. and Yamada, Y. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res., 56, 2809-2814 (1996).
23. Trask, D. K. and Muller, M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA, 85, 1417-1421 (1988).
24. Labarca, C. and Paigen, K. A simple, rapid, sensitive DNA assay procedure. Anal. Biochem., 102, 344-352 (1980).
25. Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y. and Nomura, T. Evaluation of antitumor activity in a human breast tumor/ nude mouse model with a special emphasis on treatment dose. Cancer, 64, 1577-1582 (1989).
26. Inaba, M. Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents. Jpn. J. Cancer Chemother., 18, 1449-1456 (1991).
27. Marcus, R., Peritz, E. and Gabriel, K. R. On closed testing procedures with special reference to ordered analysis of variance. Biometrika, 63, 655-660 (1976).
28. Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika, 75, 800-802 (1988).
29. Zwelling, L. A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., Parker, E., Silberman, L., Radciffe, A., Beran, M. and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J. Biol. Chem., 264, 16411-16420 (1989).
30. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
31. Jensen, P. B., Roed, H., Skovsgaard, T., Friche, E., Vindelov, L., Hansen, H. H. and Spang-Thomsen, M. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother. Pharmacol., 27, 194-198 (1990).
32. Staroselsky, A. M., Fan, D., O'Brian, C. A., Bucana, C. D., Gupta, K. P. and Fidler, I. J. Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res., 50, 7775-7780 (1990).
33. Wilmanns, C., Fan, D., O'Brian, C. A., Bucana, C. D. and Fidler, I. J. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int. J. Cancer, 52, 98-104 (1992).
34. Mattern, J., Bak, M., Hahn, E. W. and Volm, M. Human tumor xenografts as models for drug testing. Cancer Metastasis Rev., 7, 263-284 (1988).
35. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375 (1989).
36. Tanabe, K., Ikegami, Y., Ishida, R. and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res., 51, 4903-4908 (1991).
37. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D. and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226, 466-468 (1984).
38. Nelson, E. M., Tewey, K. M. and Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II by 4′-(9-acridinylamino)methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA, 81, 1361-1365 (1984).
39. Jensen, P. B., Sorensen, B. S., Demant, E. J. F., Sehested, M., Jensen, P. S., Vindelov, L. and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(acridinylamino)methanesulfon-m-amisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50, 3311-3316 (1990).
40. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
41. Strauss, G., Pagani, O., Sessa, C., Lund, B., Cavalli, F. and Hansen, H. H. A phase I study of intoplicine (RP60475F, NSC D 645008) administered on a daily X 5 schedule. Proc. Am. Assoc. Cancer Res., 34, A1378 (1993).
42. Utsugi, T., Aoyagi, K., Furune, Y., Sano, M., Wierzba, K., Okazaki, S., Asao, T. and Yamada, Y. Antitumor activity of TAS-103, a novel topoisomerase I and II inhibitor. Proc. Am. Assoc. Cancer Res., 37, 2915 (1996).